Edition:
United Kingdom

CytRx Corp (CYTR.OQ)

CYTR.OQ on NASDAQ Stock Exchange Capital Market

1.70USD
20 Apr 2018
Change (% chg)

$-0.04 (-2.02%)
Prev Close
$1.74
Open
$1.68
Day's High
$1.73
Day's Low
$1.66
Volume
18,881
Avg. Vol
58,913
52-wk High
$5.99
52-wk Low
$1.45

Chart for

About

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue... (more)
No analyst recommendations are available for .

Overall

Beta: 2.34
Market Cap(Mil.): $69.25
Shares Outstanding(Mil.): 165.83
Dividend: --
Yield (%): --

Financials

  CYTR.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -0.41 -- --
ROI: -112.76 1.58 14.38
ROE: -214.05 2.41 16.07

BRIEF-Cytrx Presents Statistically Significant Breakthrough Data For Its Albumin Binding Ultra High Potency Ladr Drug Candidates

* CYTRX PRESENTS STATISTICALLY SIGNIFICANT BREAKTHROUGH DATA FOR ITS ALBUMIN BINDING ULTRA HIGH POTENCY LADR DRUG CANDIDATES

18 Apr 2018

BRIEF-CytRx Selects Four New LADR™ Ultra High Potency Drug Candidates For Advancement Toward Clinical Trials

* CYTRX SELECTS FOUR NEW LADR™ ULTRA HIGH POTENCY DRUG CANDIDATES FOR ADVANCEMENT TOWARD CLINICAL TRIALS

15 Mar 2018

BRIEF-Cytrx Corp Announces Its Entry Into A Definitive Agreement With Destum Partners

* CYTRX CORP - ANNOUNCED ITS ENTRY INTO A DEFINITIVE AGREEMENT WITH DESTUM PARTNERS

28 Feb 2018

BRIEF-Cytrx announces new shareholder initiatives

* Cytrx Corporation provides business update and announces new shareholder initiatives

13 Nov 2017

BRIEF-Cytrx reports strategic realignment of clinical development team

* Cytrx announces strategic realignment of clinical development team

06 Nov 2017

BRIEF-Cytrx Corp announces reverse stock split

* Cytrx Corp- ‍1-for-6 reverse​ stock split will become effective as of commencement of trading on Wednesday, November 1, 2017 Source text for Eikon: Further company coverage:

31 Oct 2017

Earnings vs. Estimates